| Description | PRL-3 Inhibitor I (BR-1) is a phosphatase of regenerating liver 3 (PRL-3) inhibitor which blocks the migration and invasion of metastatic cancer cells. |
| In vitro | PRL-3 inhibitor, in a dose-dependent fashion, blocked the dephosphorylation of DiFMUP by PRL-3 and strongly suppressed the activity of PRL-3 phosphatase in PRL-3 overexpressing DLD-1 colon tumor cells [DLD-1 (PRL-3)]. Also, PRL-3 inhibitor dose-dependently blocked the migration of DLD-1 (PRL-3) cells, however, it did not inhibit the proliferation of DLD-1(PRL-3) cells, suggesting that PRL-3 inhibitor significantly blocked cell immigration and invasion without cytotoxicity |
| Target activity | PRL3:0.9 μM (IC50) |
| Synonyms | PRL-3 Inhibitor, BR-1 |
| molecular weight | 485.21 |
| Molecular formula | C17H11Br2NO2S2 |
| CAS | 893449-38-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/mL (113.35 mM) |
| References | 1. Min G , Lee S K , Kim H N , et al. Rhodanine-based PRL-3 inhibitors blocked the migration and invasion of metastatic cancer cells[J]. Bioorganic & Medicinal Chemistry Letters, 2013, 23(13):3769-3774. |